[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.125.253. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 335
Citations 0
News From the Food and Drug Administration
May 3, 2016

Treating and Preventing Anthrax

JAMA. 2016;315(17):1826. doi:10.1001/jama.2016.4484

A new agent used to treat and prevent inhalational anthrax has received FDA approval.

Obiltoxaximab, marketed as Anthim, is given by injection and used with appropriate antibacterial drugs to treat inhalational anthrax, which often is deadly. The condition results from inhaling spores of the Bacillus anthracis bacterium.

In the body, the bacteria replicate and produce toxins that cause massive, irreversible tissue injury and death. A monoclonal antibody, obiltoxaximab neutralizes those toxins (http://1.usa.gov/1UJdLzD). Inhalational anthrax is rare but may occur after exposure to infected animals or contaminated animal products.

First Page Preview View Large
First page PDF preview
First page PDF preview
×